<DOC>
	<DOCNO>NCT00520572</DOCNO>
	<brief_summary>The purpose study confirm AZD9056 effective treat rheumatoid arthritis regard sign symptom determine dose favourable 6-month treatment period . Patients receive background treatment either Methotrexate Sulphasalazine</brief_summary>
	<brief_title>A 6-month Randomised , Double-blind , Open Arm Comparator , Phase IIb , With AZD9056 , Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis RA active disease define : ≥4 swollen joint ≥6 tender/painful joint , either ( blood test ) elevate erythrocyte sedimentation rate ( ESR ) Creactive protein ( CRP ) . At least one following : documented history current presence positive rheumatoid factor ( blood test ) , baseline radiographic erosion . Be receive either oral ( tablet ) subcutaneous/intramuscular ( injection ) methotrexate least 6 month prior randomisation . Any inflammatory disease addition RA may interfere study ( e.g . polymyalgia rheumatica , giant cell arteritis , reactive arthritis , e c ) . Current chronic pain disorder include fibromyalgia chronic fatigue syndrome . Persistently abnormal liver function enzyme ( blood test ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>